Abstract: A study was performed to investigate whether expression of aquaporin (AQP) 3 and 5 has potential as a marker for distinguishing dry mouth from Sjögren's syndrome. Twenty-five patients underwent labial minor salivary gland biopsy (dry mouth, n = 9; Sjögren's syndrome, n = 16; control, n = 8). All patients were interviewed about their medical history and subjective oral symptoms, and intraoral examinations were conducted. Quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry were used to examine the expression and localization of AQP3 and 5. Significant differences in oral dryness, dry eye, medical history, and Saxon test results were revealed among the groups. However, there were no significant inter-group differences in expression of mRNA for AQP3 and 5. Immunohistochemical staining for AQP3 was localized mainly in the basolateral and part of the ductal cell membrane, and was barely evident in the apical membrane of acinar cells. AQP5 was localized to the basolateral and apical membrane and cytoplasm, but not the ductal cell membrane. Staining intensity for AQP3 in the apical membrane was significantly stronger in Sjögren's syndrome, and that for AQP5 was significantly weaker in dry mouth. Taken together, the present data suggest that expression of AQP3 and 5 may be a marker for distinguishing between patients with dry mouth and those with Sjögren's syndrome.
Introduction
Xerostomia is a subjective sensation of mouth dryness, unlike hyposalivation, which is the term used to describe an objective decrease in salivary secretion (1) . The sensation of mouth dryness is sometimes, but not necessarily accompanied by a reduction in salivary flow (2) . The symptoms of xerostomia include halitosis, oral soreness and burning, difficulty in swallowing and talking, and an altered taste sensation. As a result, xerostomia can reduce the quality of life. It has been reported that about 20% of the general population experience mouth dryness (2) . Therefore, an understanding of xerostomia and effective treatment are important. As xerostomia has various symptoms that can be detected by different examination methods, standardized methods for diagnosis and treatment have not been established.
Xerostomia has been associated with various diseases and aging (3) (4) (5) . One of the most common diseases characterized by salivary gland impairment is Sjögren's syndrome (SS), an autoimmune inflammatory disease characterized by glandular hypofunction, dry mouth, and dry eyes. Salivary gland biopsies show salivary and lacrimal gland tissue reduction with lymphocytic infiltration (6, 7) . In Japan, the diagnostic criteria for SS were revised in 2004 by a research team from the Ministry of Health, Labour and Welfare (8) . The American-European Consensus Group issued a new standard in 2002 with the goal of standardizing the diagnosis of SS worldwide (9) . Primary SS presents alone, whereas secondary SS occurs in connection with autoimmune rheumatic diseases. In addition, the symptoms do not always present concurrently. This diversity of symptomatic expression adds to the difficulty of initial diagnosis (10) . It is not always easy to distinguish SS from other forms of xerostomia. Indeed, other two sets of criteria have been proposed in the last decade, including the 2012 American College of Rheumatology (ACR) criteria (11) and the latest set in 2016 by the ACR in association with the European League against Rheumatism (EULAR) (12) .
The aquaporins (AQPs) are a family of water-specific membrane channel proteins found in almost all internal organs (13) . AQPs respond to osmotic pressure and play an important role in the rapid transfer of water across cell membranes. Currently, 13 isoforms (AQPs 0-12) have been identified in mammals (13) (14) (15) . AQPs 3 and 5 are expressed in the human salivary gland and play an important role in saliva secretion (16) . Some investigators have demonstrated that changes in the localization pattern of AQP5 cause the salivation disorder seen in SS patients (17) . However, data on the expression, localization, and role of AQP3 and 5 in the salivary gland have been conflicting. In the present study we hypothesized that expression of AQP3 and 5 could be a potential marker for distinguishing patients with dry mouth from those with SS.
Materials and Methods

Participant characteristics
Between September 2011 and June 2014 at the Department of Oral and Maxillofacial Surgery, Shimane University Hospital, samples were collected from 25 patients with a chief complaint of dry mouth. All of the patients underwent labial minor salivary gland biopsy and were examined according to the revised Japanese criteria of the Research Committee on SS of the Japanese Ministry of Health and Welfare (Table 1 ) (8) under a suspected diagnosis of SS. Surgical samples were fixed in 10% formalin, dehydrated, and embedded in paraffin wax.
In accordance with the revised Japanese criteria for SS (8) , if at least 50 lymphocytes were demonstrable in a 4-mm 2 glandular section by hematoxylin and eosin staining, and at least one other criterion was positive, SS was diagnosed. The results of SS diagnosis are shown in Table 2 .
Sixteen patients were diagnosed as having SS. Nine patients who had no history of autoimmune disease or radiotherapy of the head and neck, and did not fit the diagnostic criteria for SS but had hyposalivation and xerostomia were diagnosed as having dry mouth (DM). Eight patients who had undergone cystectomy of a lower lip mucus retention cyst without head and neck radiotherapy, and had no symptoms of dry mouth, hyposalivation, or medication were used as normal controls (18) . For ethical reasons it was, of course, difficult to obtain "normal" specimens of glandular tissue as control samples.
This study conformed to the ethical guidelines for epidemiological research issued by the MHLW and the Ministry of Education, Culture, Sports, Science and 
Oral examination
All patients were interviewed about their medical history and subjective oral symptoms (oral dryness, thirst, drinking a large amount of water, hyposalivation, difficulty swallowing dry food, dysgeusia, intraoral pain, dry eye, medical history, dry nose, cough, muscle pain, arthralgia, dry skin, rash) and underwent an intraoral examination (high prevalence of caries, atrophy of the oral mucosa, atrophy of the tongue papillae, angular chelitis, tongue coat, tongue pain, fissured tongue, geographic tongue, redness of the oral mucosa and tongue, dry mouth and dry tongue, halitosis, and redness of the opening of the parotid duct). Oral examinations (Table 3) were conducted with the aid of a dental mirror under optimal lighting while patients were seated in a dental chair.
Salivary flow volume
Gum tests and Saxon tests were performed for all patients. For the gum test, participants were instructed to chew mint-flavored gum for 10 min, then to bite down on a folded, weighed piece of gauze for 2 min. The gauze and a laboratory dish containing the remaining intraoral saliva were then weighed. Hyposalivation was defined as a flow rate of ≤10 mL in 10 min by the gum test or ≤2 g in 2 min by the Saxon test.
Expression levels of aquaporin 3 and 5 mRNA determined using qRT-PCR Labial minor salivary gland tissues taken at the time of biopsy or cystectomy from 2011 through 2014 were subjected to mRNA analysis. A total of 33 frozen samples (50 mg each) were analyzed for AQP3 and 5 transcript expression by qRT-PCR using the Taqman system (Life Technologies, Tokyo, Japan). Total RNA (1 µg per sample) was extracted from frozen tissues by homogenization using Sepasol-RNA I SuperG reagent (Nakarai Tesque, Kyoto, Japan), and cDNA was synthesized from the mRNA in accordance with the manufacturer's protocol. Levels of AQP3 and 5 expression and the internal reference, beta-actin, were measured by PCR using the ReverTra Ace kit and the ABI PRISM 7500 Sequence Detection System.
Immunohistochemical staining and image analysis
Dewaxed 4-µm-thick tissue sections were incubated for 30 min in 0.3% hydrogen peroxide in methanol to quench endogenous peroxidase activity. Pretreatment consisted of autoclave antigen retrieval in phosphate-buffered saline (phosphate-buffered salt tablets, pH 7.4; TAKARA BIO Inc., Kusatsu, Japan). The following antibodies were used: rabbit polyclonal anti-C-terminus of human AQP3 (1:500 dilution incubated for 1 h at room temperature; Abcam, Cambridge, MA, USA), rabbit monoclonal anti-C-terminus of human AQP5 (1:200 dilution incubated for 16 h at 4°C), and secondary antibody (30 min incubation at room temperature, Histofine MAX-PO [M]; Nichirei, Tokyo, Japan). Sections were then incubated in a substrate solution consisting of 0.05% diaminobenzidine tetrahydrochloride. Counterstaining was done with Mayer's hematoxylin for 30 s. Negative controls for immunohistochemistry were incubated with phosphatebuffered saline instead of the primary antibodies, and showed no positive reaction.
The areas (mm 2 ) of AQP3 and 5 immunostaining were quantified under high magnification (×40 objective lens) using a standard light microscope to ensure measurement quality. Four square areas (3 × 3 mm) including the apical, basolateral, and ductal cell membranes and cytoplasm of the labial minor salivary gland were randomly selected on the screen. The intensity of AQP3 and 5 immunoreactivity was then evaluated using Image J software (Version 1.47, National Institutes of Health, Bethesda, MD, USA) by analyzing the brightness of each pixel in RGB images, high values indicating weak intensity and low values strong intensity. The mean intensity of the four square areas was then calculated (Fig. 1) .
Statistical analysis
Continuous and categorical variables are shown as means ± standard deviations (SDs) and as frequencies and percentages, respectively. Results were compared among the groups using the Wilcoxon rank sum test or KruskalWallis test (when the number of groups was 2 or ≥3, respectively) for continuous variables, and Fisher's exact test for categorical variables. To investigate whether the combination of AQP3 and 5 expression levels in certain regions distinguished the three groups, we performed conditional inference tree analysis. Differences at P ≤ 0.05 were considered statistically significant. All statistical analyses were performed using SAS (Version 9.3, Cary, NC, USA) and R (Version 3.2.2, R Foundation, Vienna, Austria) with "ctree" as the library.
Results
Participant characteristics and oral examination findings
The characteristics of the participants are shown in Table  3 . The study subjects comprised 33 patients, including eight controls (three male, five female, 25.0 ± 25.2 years old), nine with DM (three male, six female, 67.1 ± 13.1 years old), and 16 with SS (16 female, 67.7 ± 11.8 years old). There were significant differences in age and sex among the groups (P = 0.005 and P = 0.014, respectively). With regard to subjective symptoms and intraoral findings, significant differences among the groups were revealed for oral dryness (control, 0; DM, 9 
Salivary flow volume
Significant differences were found among the groups for the Saxon test (control, 4.6 ± 2.4 g in 2 min; DM, 2.3 ± 1.9 g in 2 min; SS, 1.4 ± 0.9 g in 2 min; P = 0.004, Table  4 ), but not the gum test (control, 17.9 ± 7.6 mL in 10 min; DM, 11.6 ± 8.5 mL in 15 min; SS, 10.7 ± 5.9 mL in 15 min; P = 0.122, Table 4 ). There was a significant difference between the control and SS groups (P = 0.005, Fig. 2 ).
Expression of AQP3 and 5 mRNA
There was no significant difference in the mRNA expression of AQP3 (control, 0.64 ± 1.33; DM, 0.08 ± 0.05; SS, 0.27 ± 0.467; P = 0.264, Table 4 ) or AQP5 (control, 0.58 ± 0.53; DM, 0.20 ± 0.18; SS, 0.24 ± 0.23; P = 0.069, Table 4 ) among the three participant groups. Table 3 . The asterisk (*) indicates P < 0.05 in the Wilcoxon rank sum test. Table 3 . Continuous variables are given as mean ± SD. The asterisk (*) indicates P < 0.05 in the Kruskal-Wallis test.
Localization of AQP3 and 5
In the control group, AQP3 was localized to the basolateral cell membrane (BM) of acinar cells and part of the ductal cell membrane (DC), and was barely expressed in the apical cell membrane (AM) and cytoplasm (CP) of acinar cells (Fig. 3) . AQP5 was localized to the BM, AM, and CP of acinar cells, but was not evident in the DM (Fig. 3) .
Intensity of AQP3 and 5 immunoreactivity
The intensity of AQP3 and 5 immunoreactivity in the apical and basolateral cell membranes of acinar cells and in the ductal cell membrane was compared among the groups (Table 4 ). The intensity of AQP3 immunoreactivity in the apical cell membrane of acinar cells and the ductal cell membrane was significantly stronger in the SS group than in the control and DM groups (apical cell membrane: control, 172.8 ± 3.6; DM, 176.8 ± 9.2; SS, 180.7 ± 6.3; ductal cell membrane: control, 133.7 ± 9.4; DM, 133.3 ± 11.4; SS, 116.9 ± 14.9; P = 0.037 and P = 0.022, respectively, Table 4 ). The intensity of AQP5 immunoreactivity in the apical cell membrane of acinar cells and the cytoplasm was significantly weaker in the DM group than in the control and SS groups (apical cell membrane: control, 134.6 ± 9.0; DM, 108.3 ± Fig. 3 Localization of AQP3 and 5 in human labial salivary glands. Abbreviations are as used in Table 3 . AQP3 was localized to the basolateral cell membrane (BM) of acinar cells and part of the ductal cell membrane (DC) in patients with DM and SS, and was barely seen in the apical cell membrane (AM) and cytoplasm (CP) of acinar cells in the control group. AQP5 was localized to the BM, AM, and CP of acinar cells, but was not seen in the DC among the three participant groups. All scale bars indicate 100 μm. Magnification: ×20. Tables. 18.6; SS, 132.7 ± 22.1; cytoplasm: control, 155.2 ± 7.6; DM, 139.7 ± 17.6; SS, 157.7 ± 10.8; P = 0.011 and P = 0.009, respectively, Table 4 ). The intensity of AQP3 immunoreactivity in the apical cell membrane of acinar cells did not differ significantly between the control and SS groups (P = 0.005, Fig. 4A ). The intensity of AQP3 immunoreactivity in the ductal cell membrane showed a significant difference between DM and SS (Fig. 4B) . The intensity of AQP5 immunoreactivity in the apical cell membrane differed significantly between the control and DM, and the DM and SS groups (P = 0.018, P = 0.005, respectively, Fig. 4C ). The intensity of AQP5 immunoreactivity in the cytoplasm differed significantly between the control and DM, and the DM and SS groups (P = 0.018, P = 0.004, respectively, Fig. 4 D) .
Tree analysis showed that the combination of AQP3 (P = 0.011) and AQP5 (P = 0.016) in the apical cell membrane of acinar cells was able to distinguish the three groups (Fig. 5) . The subgroup showing an intensity of AQP5 immunoreactivity of ≤107.501 included seven out of eight (87.5%) patients with DM, the subgroup with AQP5 > 107.501 and AQP3 ≤ 174.407 included five out of six (83.3%) healthy participants, and the subgroup with AQP5 > 107.501 and AQP3 > 174.407 included 14 out of 19 (78.9%) patients with SS.
Discussion
In this study, there were significant differences in the characteristics of the participant groups, including oral dryness, dry eye, and dry mouth and tongue (Table 3) . These results supported the classification of the participants' clinical diagnoses based on the criteria for DM and SS.
AQP3 mRNA has been detected by RT-PCR in normal and SS human labial salivary glands, but not in patients with DM (16, 19, 20) . Gresz et al. (16) reported that in normal individuals, AQP3 was localized to the basolateral cell membrane but not the apical cell membrane of labial acinar salivary gland cells, and was not detected in the ductal cell membrane. In addition, Beroukas et al. (19) reported that immunohistochemical expression of AQP3 in salivary gland cells was similar in individuals with and without SS. In our study, the expression of AQP3 mRNA was similar among the participant groups, and AQP3 was localized to the basolateral cell membrane (and to a lesser extent, the apical cell membrane) in acinar cells, and to the basolateral cell membrane in ductal cells. The distribution of AQP3 determined by immunohistochemical assay, including previous reports and ours, is summarized in Table 5 . The detection of AQP3 in the ductal cell membrane in the present study differs from previous reports (16, 19) . Furthermore, AQP3 staining intensity in the apical cell membrane of acinar cells was significantly lower in patients with SS than in controls. Although a functional role for AQP3 in salivary secretion has not been postulated previously, our data suggest that AQP3 may play an important role in saliva secretion and in the pathogenesis of dry mouth conditions, including SS.
Several investigators have reported that in normal individuals, AQP5 was localized to the apical cell membrane of serous acinar cells, and not detected in the basolateral Tables 3 and 5 . References are given in brackets. Dashes indicate "no data". cell membrane and duct cells (16, 18, 19) . The immunohistochemical distribution of AQP5 in human labial glands from individuals with and without SS has been controversial. Gresz et al. (16) demonstrated that AQP5 staining was apical at the acinar cell membrane, and that no AQP5 staining was present in the ducts of labial glands. Beroukas et al. (19) and Waterman et al. (21, 22) also demonstrated that AQP5 was localized apically in the acinar cells of patients with SS, while Steinfeld et al. (17, 23) and Xiao et al. (24) demonstrated that AQP5 was also localized to the basolateral cell membrane of acinar cells. Steinfeld et al. (17, 23) reported that AQP5 distribution was greater at the basolateral cell membrane of acinar cells in patients with SS relative to controls, but lower at the apical cell membrane of acinar cells. In patients with dry mouth in our study, AQP5 was localized to the apical cell membrane of acinar cells, but was not detected in the basolateral cell membrane (17); however, Gresz et al. (18) concluded that basolateral AQP5 staining in salivary acinar cells was nonspecific background staining, and were unable to demonstrate any altered AQP5 distribution in the salivary glands of patients with SS by immunohistochemistry. In contrast, Lee et al. (25) concluded that autoantibodies against the muscarinic type 3 receptor (M3R) in patients with SS inhibit AQP5 trafficking and detection of AQP5 expression in the apical cell membrane. The distribution of AQP5 according to immunohistochemistry and RT-PCR appears to depend on the cell lines examined, the analytical methods employed, and the sensitivity and specificity of the antibodies.
In our study, expression of AQP5 mRNA did not differ among the three groups. In the control group, AQP5 was localized mainly to the basolateral cell membrane and expressed slightly in the apical cell membrane, but was not detected in duct cells. In the DM and SS groups, AQP5 was localized to the basolateral cell membrane and slightly evident in the apical cell membrane of acinar cells, but was not localized to the ductal cell membrane. AQP5 staining intensity in the apical cell membrane of acinar cells was significantly higher in the DM group than in the control group, and was significantly lower in the SS group than in the DM group. AQP5 distribution, the numbers of participants, and the primary antibodies used in previous studies and our present study are summarized in Table 6 . The discrepancy between Gresz's conclusions and our results regarding AQP5 distribution in the acinar gland may be accounted for by differences in the antibody used and the number of study participants. Gresz et al. (16) used affinity-purified polyclonal antibodies against human AQP5, whereas we used rabbit monoclonal antibodies. More detailed studies using monoclonal antibodies against human AQP in a larger number of participants would be needed to confirm the reliability of our present findings.
In this preliminary study, tree diagram analysis showed that a high intensity of both AQP3 and 5 immunoreactivity in the apical cell membrane of acinar cells may indicate SS. Therefore, the distribution of AQP3 and 5 immunostaining in the apical cell membrane of the minor salivary gland may be a key factor to distinguish between SS and DM. As the number of cases in this study was small and this is the first report to have examined AQP5 expression using immunohistochemistry with a monoclonal antibody, further studies are encouraged.
The present study was limited by a discrepancy in the average age of individuals in the three groups. The patients with mucus retention cysts were much younger than those with SS or DM. Physiological changes in AQP with aging may have been present in the SS and DM groups, and this possibility will need to be investigated elsewhere.
In conclusion, the expression of AQP3 and 5 has potential use as a marker for distinguishing patients with DM and from those with SS.
